** Shares of GSK GSK.L up 4.5% at 1,442p - top pct gainer on the FTSE 100 index .FTSE
** The British drugmaker lifts 2031 sales target to more than 40 bln pounds from the 38 bln pounds previously expected
** Co beats Q4 earnings with core EPS of 23.2p vs IBES ests of 19.01p, on strength in its HIV and oncology portfolio
** Reports Q4 sales of 8.12 bln pounds ($10.15 bln), above IBES ests of 7.75 bln pounds
** Launches share buyback of 2 bln pounds
** Sets 2025 sales growth target of 3%-5% against analysts' expectations for growth of about 3.5%, according to a company-compiled consensus
** GSK fell about 12% in the last 12 months
($1 = 0.8002 pounds)
(Reporting by Yamini Kalia in Bengaluru)
((Yamini.Kalia@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。